ALIM Alimera Sciences

UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on Tuesday September 15, 2020 at 3:30 PM ET. To listen to the conference live, please sign up at .

An archived presentation will be available from September 16th on the Alimera website at

In addition, Mr. Eiswirth is available for virtual one-on-one meetings from September 14 – 16, 2020. To schedule a meeting please contact the conference coordinator at  .

About Alimera Sciences, Inc.

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.  For more information, please visit

For press inquiries:

Jules Abraham

for Alimera Sciences

917-885-7378



For investor inquiries:

Scott Gordon

for Alimera Sciences





EN
09/09/2020

Underlying

ALIMAlimera Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alimera Sciences

 PRESS RELEASE
Free
ALIM Alimera Science...

Alimera Sciences Reports Second Quarter 2024 Results

Alimera Sciences Reports Second Quarter 2024 Results Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not ...

August 6, 2024 1 EN
 PRESS RELEASE
Free
ALIM Alimera Science...

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5...

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Commit...

June 4, 2024 1 EN
 PRESS RELEASE
Free
ALIM Alimera Science...

Alimera Sciences Reports First Quarter 2024 Results

Alimera Sciences Reports First Quarter 2024 Results Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to...

May 14, 2024 1 EN
 PRESS RELEASE
Free
ALIM Alimera Science...

Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented ...

Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmolo...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ALIM Alimera Science...

Alimera Sciences to Report First Quarter 2024 Financial Results on May...

Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update Conference Call to be held the same day at 9:00am Eastern Time ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open. Management will host a conference call at ...

April 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch